RHONE MA HOLDINGS |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.675 MYR | -0.74% |
|
-2.17% | -2.17% |
| 05-15 | Rhone Ma's Profit Edges Up in Q1 | MT |
| 05-14 | Rhone Ma Holdings Berhad Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -2.17% | 31.71M | - | ||
| +55.19% | 815B | C+ | ||
| +46.48% | 654B | B | ||
| -6.09% | 354B | C+ | ||
| +21.92% | 337B | B- | ||
| +19.36% | 247B | B+ | ||
| +3.89% | 229B | A+ | ||
| +14.08% | 219B | B- | ||
| +10.86% | 171B | C+ | ||
| -2.78% | 159B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- RHONEMA Stock
- Ratings Rhone Ma Holdings
